title: Effect of sarcosine on antioxidant parameters and metallothionein content in the PC-3 prostate cancer cell line.
abstract: Sarcosine is currently one of the most discussed markers of prostate cancer. It is involved in amino acid metabolism and methylation processes that occur during the progression of prostate cancer. In this study, we monitored the effect of the addition of sarcosine (0; 10; 250; 500; 1,000 and 1,500 µM) in a time-dependent manner (0-72 h) on the PC-3 prostate cancer cell line. For the assessment of cell viability, the commonly used MTT test was employed. Furthermore, ion-exchange liquid chromatography was used for the determination of sarcosine content in the PC-3 cells. We also determined metallothionein (MT) levels by chip capillary electrophoresis and Brdicka reaction in the cells treated with sarcosine. Sarcosine levels in the cells increased in a concentration-dependent manner levels increased from only 270 nM with the lowest applied concentration of sarcosine (10 µM) to 106 µM with the highest applied concentration of sarcosine (1,500 µM). There was a marginal change observed in the MT concentration. Finally, the antioxidant activity of the PC-3 cells was determined using five different spectrophotometric methods [2,2-diphenyl-1-picrylhydrazyl (DPPH), ferric reducing ability of plasma (FRAP), free radicals, N,N-dimethyl-p-phenylenediamine (DMPD) and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid (ABTS)]. A significant negative correlation was observed between DPPH and FRAP (r=-0.68 at p<0.001) and between DMPD and ABST (r=-0.64 at p<0.001). Additionally, as regards the correlation between MT and DPPH, a significant positive trend (r=0.62 at p<0.001) was observed.
authors.affiliation: Department of Chemistry and Biochemistry, Faculty of Agronomy, Mendel University in Brno, CZ-613 00 Brno, Czech Republic.
authors.forename: Natalia
authors.initials: N
authors.lastname: Cernei
authors.forename: Ondrej
authors.initials: O
authors.lastname: Zitka
authors.forename: Sylvie
authors.initials: S
authors.lastname: Skalickova
authors.forename: Jaromir
authors.initials: J
authors.lastname: Gumulec
authors.forename: Marketa
authors.initials: M
authors.lastname: Sztalmachova
authors.forename: Miguel Angel Merlos
authors.initials: MA
authors.lastname: Rodrigo
authors.forename: Jiri
authors.initials: J
authors.lastname: Sochor
authors.forename: Michal
authors.initials: M
authors.lastname: Masarik
authors.forename: Vojtech
authors.initials: V
authors.lastname: Adam
authors.forename: Jaromir
authors.initials: J
authors.lastname: Hubalek
authors.forename: Libuse
authors.initials: L
authors.lastname: Trnkova
authors.forename: Jarmila
authors.initials: J
authors.lastname: Kruseova
authors.forename: Tomas
authors.initials: T
authors.lastname: Eckschlager
authors.forename: Rene
authors.initials: R
authors.lastname: Kizek
mesh_terms: D014408:Biomarkers, Tumor / Q000494:pharmacology / Q000502:physiology*; D045744:Cell Line, Tumor; D002470:Cell Survival; D016166:Free Radical Scavengers / Q000378:metabolism*; D006801:Humans; D008297:Male; D008668:Metallothionein / Q000378:metabolism*; D011471:Prostatic Neoplasms; D012521:Sarcosine / Q000494:pharmacology / Q000502:physiology*
chemical_list: D014408:Biomarkers, Tumor; D016166:Free Radical Scavengers; D008668:Metallothionein; D012521:Sarcosine